Intraocular anti-vascular endothelial growth factor (VEGF) therapy is commonly used because of its efficacy in various diseases such as choroidal neovascularization, retinal vascular occlusion, and diabetic retinopathy/macular edema. This evidence concerns the gene VEGFA and retinal vein occlusion.